Capricor Therapeutics (CAPR) Misses Q2 EPS by 10c

Capricor Therapeutics (NASDAQ: CAPR) reported Q2 EPS of ($0.70), $0.10 worse than the analyst estimate of ($0.60).

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Interactive Brokers (IBKR) call put ratio 1 call 2.5 puts with a focus on October 84, 85 and 90 puts
• Stifel Reiterates Buy Rating on Lumentum (LITE)